Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
2.1M
Short interest
settlement 2026-10-15
3.2
Days to cover
+0.7 days vs prior
55.3%
Short share of volume
2026-11-02
8
Fails to deliver
settlement 2026-09-17
Fri 29 Jan
Next earnings
estimated date
-$6.5M
Insider flow, 90 days
0 buys, 32 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in REGN is 2,134,934 shares, down 391,512 shares over the last month. Over the last 48 readings it ranged from 1,785,884 shares (15 November 2024) to 3,501,203 shares (15 July 2026). At the reported average volume of 671K shares a day that is 3.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/regn" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 2,134,934 | -0.7% | 670,714 | 3.18 |
| 2026-09-30 | 2,150,303 | -14.9% | 863,842 | 2.49 |
| 2026-09-15 | 2,526,446 | -1.0% | 571,271 | 4.42 |
| 2026-08-31 | 2,552,029 | +6.5% | 662,864 | 3.85 |
| 2026-08-14 | 2,396,152 | -29.2% | 760,654 | 3.15 |
| 2026-07-31 | 3,385,841 | -3.3% | 858,662 | 3.94 |
| 2026-07-15 | 3,501,203 | +0.2% | 741,224 | 4.72 |
| 2026-06-30 | 3,494,420 | +5.8% | 1,199,840 | 2.91 |
| 2026-06-15 | 3,304,329 | +10.1% | 968,690 | 3.41 |
| 2026-05-29 | 3,001,968 | +8.0% | 1,532,432 | 1.96 |
| 2026-05-15 | 2,780,809 | -15.0% | 764,041 | 3.64 |
| 2026-04-30 | 3,270,341 | +15.1% | 805,112 | 4.06 |
| 2026-04-15 | 2,841,780 | +11.5% | 651,908 | 4.36 |
| 2026-03-31 | 2,548,311 | +4.0% | 604,079 | 4.22 |
| 2026-03-13 | 2,451,498 | +7.2% | 586,546 | 4.18 |
| 2026-02-27 | 2,286,750 | +11.4% | 606,073 | 3.77 |
| 2026-02-13 | 2,051,997 | -5.7% | 823,603 | 2.49 |
| 2026-01-30 | 2,176,530 | -4.9% | 929,677 | 2.34 |
| 2026-01-15 | 2,289,214 | -7.8% | 894,421 | 2.56 |
| 2025-12-31 | 2,484,091 | -9.3% | 753,196 | 3.30 |
| 2025-12-15 | 2,738,113 | -13.0% | 974,712 | 2.81 |
| 2025-11-28 | 3,148,430 | +10.7% | 1,292,803 | 2.44 |
| 2025-11-14 | 2,844,265 | +1.8% | 960,953 | 2.96 |
| 2025-10-31 | 2,793,459 | -4.6% | 1,014,914 | 2.75 |
| 2025-10-15 | 2,927,169 | +6.0% | 1,188,676 | 2.46 |
| 2025-09-30 | 2,760,203 | -7.5% | 1,168,677 | 2.36 |
| 2025-09-15 | 2,985,318 | +5.6% | 960,752 | 3.11 |
| 2025-08-29 | 2,827,689 | +20.4% | 959,124 | 2.95 |
| 2025-08-15 | 2,349,138 | +2.5% | 1,061,943 | 2.21 |
| 2025-07-31 | 2,291,886 | +10.5% | 920,278 | 2.49 |
| 2025-07-15 | 2,074,491 | -7.9% | 843,455 | 2.46 |
| 2025-06-30 | 2,252,720 | +10.9% | 1,145,697 | 1.97 |
| 2025-06-13 | 2,031,432 | -24.7% | 1,604,736 | 1.27 |
| 2025-05-30 | 2,697,824 | -3.6% | 1,415,430 | 1.91 |
| 2025-05-15 | 2,798,186 | -3.1% | 1,513,283 | 1.85 |
| 2025-04-30 | 2,887,463 | +11.0% | 1,200,347 | 2.41 |
| 2025-04-15 | 2,601,922 | -6.8% | 1,222,372 | 2.13 |
| 2025-03-31 | 2,790,935 | -14.1% | 948,927 | 2.94 |
| 2025-03-14 | 3,249,157 | +26.6% | 1,030,984 | 3.15 |
| 2025-02-28 | 2,565,723 | +16.4% | 778,843 | 3.29 |
| 2025-02-14 | 2,204,900 | +0.8% | 1,068,824 | 2.06 |
| 2025-01-31 | 2,187,734 | +3.3% | 913,424 | 2.40 |
| 2025-01-15 | 2,117,354 | +1.0% | 834,775 | 2.54 |
| 2024-12-31 | 2,095,552 | +11.5% | 852,546 | 2.46 |
| 2024-12-13 | 1,879,771 | +4.5% | 849,615 | 2.21 |
| 2024-11-29 | 1,799,097 | +0.7% | 838,083 | 2.15 |
| 2024-11-15 | 1,785,884 | -3.6% | 817,313 | 2.19 |
| 2024-10-31 | 1,852,823 | +8.0% | 852,996 | 2.17 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of REGN volume is 55.3%, up 16.8 points over the last five sessions. Over the last 30 readings it ranged from 38.5% (26 October 2026) to 60.7% (20 October 2026). The latest reading is 7.2 points above the 30-session average of 48.1%, on 787K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 436K | 787K | 55.3% | 206,801 |
| 2026-10-30 | 597K | 1.2M | 48.8% | 171,914 |
| 2026-10-29 | 173K | 295K | 58.6% | 4,764 |
| 2026-10-28 | 82K | 143K | 57.4% | 1,844 |
| 2026-10-27 | 89K | 221K | 40.1% | 1,411 |
| 2026-10-26 | 57K | 148K | 38.5% | 601 |
| 2026-10-23 | 65K | 150K | 43.5% | 435 |
| 2026-10-22 | 189K | 325K | 58.1% | 7,951 |
| 2026-10-21 | 124K | 211K | 58.7% | 1,687 |
| 2026-10-20 | 130K | 214K | 60.7% | 3,870 |
| 2026-10-19 | 97K | 170K | 57.0% | 292 |
| 2026-10-16 | 92K | 227K | 40.7% | 684 |
| 2026-10-15 | 147K | 294K | 50.0% | 4,332 |
| 2026-10-14 | 150K | 317K | 47.5% | 1,455 |
| 2026-10-13 | 91K | 216K | 42.0% | 598 |
| 2026-10-12 | 103K | 261K | 39.2% | 1,866 |
| 2026-10-09 | 89K | 191K | 46.7% | 1,306 |
| 2026-10-08 | 106K | 225K | 47.3% | 447 |
| 2026-10-07 | 117K | 258K | 45.4% | 133 |
| 2026-10-06 | 95K | 211K | 45.0% | 770 |
| 2026-10-05 | 135K | 258K | 52.2% | 163 |
| 2026-10-02 | 134K | 258K | 52.0% | 729 |
| 2026-10-01 | 173K | 399K | 43.4% | 366 |
| 2026-09-30 | 120K | 269K | 44.4% | 500 |
| 2026-09-29 | 153K | 298K | 51.3% | 458 |
| 2026-09-28 | 159K | 377K | 42.2% | 34 |
| 2026-09-25 | 98K | 226K | 43.3% | 721 |
| 2026-09-24 | 76K | 165K | 46.3% | 1,252 |
| 2026-09-23 | 93K | 210K | 44.3% | 481 |
| 2026-09-22 | 99K | 227K | 43.8% | 910 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 17 September 2026, the fails-to-deliver balance in REGN is 8 shares, down 333 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (15 April 2026) to 2,016 shares (18 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-17 | 8 | $774.61 | $6K |
| 2026-09-09 | 341 | $810.31 | $276K |
| 2026-09-03 | 1,556 | $852.03 | $1.3M |
| 2026-08-20 | 21 | $840.84 | $18K |
| 2026-08-18 | 2,016 | $805.93 | $1.6M |
| 2026-08-14 | 60 | $805.97 | $48K |
| 2026-08-10 | 1,444 | $784.36 | $1.1M |
| 2026-08-03 | 132 | $762.63 | $101K |
| 2026-07-31 | 1,276 | $738.34 | $942K |
| 2026-07-30 | 1 | $695.42 | $695 |
| 2026-07-24 | 28 | $651.91 | $18K |
| 2026-07-23 | 28 | $651.18 | $18K |
| 2026-07-22 | 28 | $675.19 | $19K |
| 2026-07-20 | 52 | $676.69 | $35K |
| 2026-06-30 | 9 | $631.81 | $6K |
| 2026-06-29 | 56 | $632.90 | $35K |
| 2026-06-22 | 19 | $609.94 | $12K |
| 2026-06-11 | 1 | $601.65 | $602 |
| 2026-06-04 | 325 | $618.95 | $201K |
| 2026-05-26 | 662 | $638.88 | $423K |
| 2026-05-18 | 160 | $698.25 | $112K |
| 2026-05-13 | 1,542 | $723.41 | $1.1M |
| 2026-05-11 | 1 | $714.89 | $715 |
| 2026-05-07 | 151 | $721.05 | $109K |
| 2026-05-04 | 4 | $701.42 | $3K |
| 2026-04-15 | 1 | $755.51 | $756 |
| 2026-03-30 | 14 | $737.71 | $10K |
| 2026-03-27 | 23 | $756.73 | $17K |
| 2026-03-25 | 10 | $741.69 | $7K |
| 2026-03-23 | 14 | $732.87 | $10K |
Insider trades
SEC Form 4, newest first. JSONInsiders at REGN reported 32 open-market sells worth $6.5M in the last 90 days and no open-market buys. Latest filing: MURPHY ANDREW J (Co-Chief Scientific Officer) on 2026-10-14.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 50 | $781.47 | $39K | 48K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 463 | $780.63 | $361K | 48K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 380 | $779.59 | $296K | 48K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 454 | $778.64 | $354K | 49K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 38 | $777.76 | $30K | 49K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 66 | $776.31 | $51K | 49K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 376 | $775.46 | $292K | 49K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 121 | $774.48 | $94K | 50K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 224 | $773.40 | $173K | 50K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 211 | $772.56 | $163K | 50K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 283 | $771.56 | $218K | 50K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 12 | $770.20 | $9K | 50K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 127 | $769.30 | $98K | 51K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 105 | $768.33 | $81K | 51K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 192 | $767.39 | $147K | 51K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 279 | $766.47 | $214K | 51K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 271 | $765.39 | $207K | 51K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 219 | $764.40 | $167K | 51K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 25 | $763.76 | $19K | 52K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 55 | $762.57 | $42K | 52K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 27 | $761.36 | $21K | 52K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 74 | $760.65 | $56K | 52K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 14 | $759.96 | $11K | 52K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 24 | $758.16 | $18K | 52K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 16 | $757.68 | $12K | 52K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 35 | $755.91 | $26K | 52K |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | Sell | 6 | $753.76 | $5K | 52K |
| 2026-10-13 | MURPHY ANDREW J | Co-Chief Scientific Officer | Tax withholding | 13K | $754.58 | $9.7M | 52K |
| 2026-10-13 | MURPHY ANDREW J | Co-Chief Scientific Officer | Exercise or conversion | 17K | $381.92 | $6.5M | 65K |
| 2026-09-03 | McCourt Marion | EVP Commercial | Sell | 1K | $857.39 | $970K | 12K |
| 2026-09-02 | McCourt Marion | EVP Commercial | Sell | 1K | $850.00 | $1.0M | 13K |
| 2026-09-02 | Guarini Kathryn | Director | Sell | 400 | $850.00 | $340K | 603 |
| 2026-09-02 | Guarini Kathryn | Director | Exercise or conversion | 400 | $719.37 | $288K | 1K |
| 2026-08-19 | LAROSA JOSEPH J | EVP General Counsel and Secret | Tax withholding | 9K | $830.15 | $7.5M | 36K |
| 2026-08-19 | LAROSA JOSEPH J | EVP General Counsel and Secret | Exercise or conversion | 12K | $381.92 | $4.7M | 45K |
| 2026-08-18 | Fenimore Christopher R. | EVP Finance CFO | Tax withholding | 5K | $813.47 | $3.7M | 20K |
| 2026-08-18 | Fenimore Christopher R. | EVP Finance CFO | Exercise or conversion | 6K | $381.92 | $2.4M | 25K |
| 2026-08-10 | Zoghbi Huda Y | Director | Sell | 800 | $800.00 | $640K | 2K |
| 2026-08-10 | Zoghbi Huda Y | Director | Exercise or conversion | 800 | $376.69 | $301K | 3K |
| 2026-08-10 | Guarini Kathryn | Director | Sell | 400 | $800.00 | $320K | 603 |
| 2026-08-10 | Guarini Kathryn | Director | Exercise or conversion | 400 | $719.37 | $288K | 1K |
| 2026-07-02 | RYAN ARTHUR F | Director | Sell | 200 | $650.15 | $130K | 17K |
| 2026-05-01 | RYAN ARTHUR F | Director | Sell | 2 | $714.13 | $1K | 18K |
| 2026-05-01 | RYAN ARTHUR F | Director | Sell | 5 | $711.49 | $4K | 18K |
| 2026-05-01 | RYAN ARTHUR F | Director | Sell | 15 | $704.28 | $11K | 18K |
| 2026-05-01 | RYAN ARTHUR F | Director | Sell | 1 | $712.09 | $712 | 18K |
| 2026-05-01 | RYAN ARTHUR F | Director | Sell | 2 | $710.87 | $1K | 18K |
| 2026-05-01 | RYAN ARTHUR F | Director | Sell | 6 | $709.45 | $4K | 18K |
| 2026-05-01 | RYAN ARTHUR F | Director | Sell | 4 | $707.40 | $3K | 18K |
| 2026-05-01 | RYAN ARTHUR F | Director | Sell | 7 | $706.74 | $5K | 18K |
| 2026-05-01 | RYAN ARTHUR F | Director | Sell | 14 | $705.56 | $10K | 18K |
| 2026-05-01 | RYAN ARTHUR F | Director | Sell | 24 | $703.46 | $17K | 18K |
| 2026-05-01 | RYAN ARTHUR F | Director | Sell | 15 | $702.46 | $11K | 18K |
| 2026-05-01 | RYAN ARTHUR F | Director | Sell | 5 | $701.76 | $4K | 18K |
| 2026-04-01 | RYAN ARTHUR F | Director | Sell | 8 | $774.58 | $6K | 18K |
| 2026-04-01 | RYAN ARTHUR F | Director | Sell | 40 | $779.71 | $31K | 18K |
| 2026-04-01 | RYAN ARTHUR F | Director | Sell | 4 | $778.24 | $3K | 18K |
| 2026-04-01 | RYAN ARTHUR F | Director | Sell | 9 | $777.42 | $7K | 18K |
| 2026-04-01 | RYAN ARTHUR F | Director | Sell | 13 | $776.62 | $10K | 18K |
| 2026-04-01 | RYAN ARTHUR F | Director | Sell | 14 | $775.58 | $11K | 18K |
| 2026-04-01 | RYAN ARTHUR F | Director | Sell | 8 | $773.59 | $6K | 18K |
| 2026-04-01 | RYAN ARTHUR F | Director | Sell | 3 | $772.76 | $2K | 18K |
| 2026-04-01 | RYAN ARTHUR F | Director | Sell | 1 | $771.32 | $771 | 18K |
| 2026-03-02 | RYAN ARTHUR F | Director | Sell | 20 | $789.28 | $16K | 18K |
| 2026-03-02 | RYAN ARTHUR F | Director | Sell | 2 | $787.34 | $2K | 18K |
| 2026-03-02 | RYAN ARTHUR F | Director | Sell | 7 | $786.61 | $6K | 18K |
| 2026-03-02 | RYAN ARTHUR F | Director | Sell | 2 | $782.62 | $2K | 18K |
| 2026-03-02 | RYAN ARTHUR F | Director | Sell | 2 | $781.21 | $2K | 18K |
| 2026-03-02 | RYAN ARTHUR F | Director | Sell | 20 | $788.96 | $16K | 18K |
| 2026-03-02 | RYAN ARTHUR F | Director | Sell | 11 | $785.48 | $9K | 18K |
| 2026-03-02 | RYAN ARTHUR F | Director | Sell | 9 | $784.48 | $7K | 18K |
| 2026-03-02 | RYAN ARTHUR F | Director | Sell | 10 | $783.62 | $8K | 18K |
| 2026-03-02 | RYAN ARTHUR F | Director | Sell | 3 | $780.69 | $2K | 18K |
| 2026-03-02 | RYAN ARTHUR F | Director | Sell | 5 | $779.69 | $4K | 18K |
| 2026-03-02 | RYAN ARTHUR F | Director | Sell | 2 | $778.30 | $2K | 18K |
| 2026-03-02 | RYAN ARTHUR F | Director | Sell | 7 | $777.46 | $5K | 18K |
| 2026-02-19 | Zoghbi Huda Y | Director | Sell | 4 | $790.00 | $3K | 2K |
| 2026-02-19 | Zoghbi Huda Y | Director | Sell | 56 | $785.61 | $44K | 2K |
| 2026-02-19 | Zoghbi Huda Y | Director | Sell | 160 | $784.45 | $126K | 2K |
| 2026-02-19 | Zoghbi Huda Y | Director | Sell | 220 | $783.29 | $172K | 2K |
| 2026-02-19 | Zoghbi Huda Y | Director | Sell | 298 | $782.10 | $233K | 2K |
| 2026-02-19 | Zoghbi Huda Y | Director | Sell | 209 | $781.28 | $163K | 2K |
| 2026-02-19 | Zoghbi Huda Y | Director | Sell | 331 | $780.45 | $258K | 3K |
| 2026-02-19 | Zoghbi Huda Y | Director | Sell | 208 | $779.55 | $162K | 3K |
| 2026-02-19 | Zoghbi Huda Y | Director | Sell | 53 | $778.47 | $41K | 3K |
| 2026-02-19 | Zoghbi Huda Y | Director | Sell | 50 | $775.50 | $39K | 3K |
| 2026-02-19 | Zoghbi Huda Y | Director | Sell | 49 | $774.68 | $38K | 3K |
| 2026-02-19 | Zoghbi Huda Y | Director | Exercise or conversion | 2K | $376.69 | $617K | 3K |
| 2026-02-09 | RYAN ARTHUR F | Director | Sell | 1 | $787.82 | $788 | 18K |
| 2026-02-09 | RYAN ARTHUR F | Director | Sell | 1 | $785.71 | $786 | 18K |
| 2026-02-09 | RYAN ARTHUR F | Director | Sell | 1 | $784.59 | $785 | 18K |
| 2026-02-09 | RYAN ARTHUR F | Director | Sell | 1 | $782.53 | $783 | 18K |
| 2026-02-09 | RYAN ARTHUR F | Director | Sell | 5 | $781.48 | $4K | 18K |
| 2026-02-09 | RYAN ARTHUR F | Director | Sell | 1 | $780.09 | $780 | 18K |
| 2026-02-09 | RYAN ARTHUR F | Director | Sell | 2 | $786.29 | $2K | 18K |
| 2026-02-09 | RYAN ARTHUR F | Director | Sell | 3 | $783.34 | $2K | 18K |
| 2026-02-09 | RYAN ARTHUR F | Director | Sell | 5 | $779.41 | $4K | 18K |
| 2026-02-09 | RYAN ARTHUR F | Director | Sell | 12 | $778.53 | $9K | 18K |
| 2026-02-09 | RYAN ARTHUR F | Director | Sell | 57 | $777.56 | $44K | 18K |
| 2026-02-09 | RYAN ARTHUR F | Director | Sell | 10 | $776.59 | $8K | 18K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON17 Form 144 notices on file for REGN worth $39.4M at the prices reported; 11 in the last 90 days worth $34.1M. Latest: Joseph LaRosa filed on 2026-11-02 to sell 4,466 shares ($4.3M) from 2026-11-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-11-02 | Joseph LaRosaOfficer | 4K | $4.3M | 0.004% | 2026-11-02 | UBS Financial Services Inc |
| 2026-11-02 | GEORGE L. SINGDirector | 21K | $20.4M | 0.021% | 2026-11-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-10-30 | McCourt MarionOfficer | 1K | $984K | 0.001% | 2026-10-30 | UBS Financial Services Inc. |
| 2026-10-30 | Guarini KathrynDirector | 400 | $360K | 0.000% | 2026-10-30 | UBS Financial Services, Inc. |
| 2026-10-30 | MICHAEL S BROWNDirector | 2K | $1.6M | 0.002% | 2026-10-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-10-14 | MURPHY ANDREW JOfficer | 4K | $3.2M | 0.004% | 2026-10-14 | UBS Financial Services, Inc. |
| 2026-09-03 | McCourt MarionOfficer | 1K | $969K | 0.001% | 2026-09-03 | UBS Financial Services Inc. |
| 2026-09-02 | McCourt MarionOfficer | 1K | $1.0M | 0.001% | 2026-09-02 | UBS Financial Services Inc. |
| 2026-09-02 | Guarini KathrynDirector | 400 | $340K | 0.000% | 2026-09-02 | UBS Financial Services, Inc. |
| 2026-08-10 | Zoghbi Huda YDirector | 800 | $640K | 0.001% | 2026-08-10 | UBS Financial Services, Inc. |
| 2026-08-10 | Guarini KathrynBoard member | 400 | $320K | 0.000% | 2026-08-10 | UBS Financial Services, Inc. |
| 2026-02-19 | Zoghbi Huda YDirector | 2K | $1.3M | 0.002% | 2026-02-19 | UBS Financial Services, Inc. |
| 2026-02-09 | Arthur F. RyanDirector | 400 | $314K | 0.000% | 2026-02-09 | J.P. Morgan Securities LLC |
| 2026-02-09 | Pitofsky JasonOfficer | 2K | $1.6M | 0.002% | 2026-02-09 | UBS Financial Services, Inc. |
| 2026-01-07 | Bassler Bonnie LDirector | 2K | $1.2M | 0.001% | 2026-01-07 | RBC CAPITAL MARKETS LLC |
| 2025-11-20 | Bassler Bonnie LDirector | 760 | $570K | 0.001% | 2025-11-20 | RBC CAPITAL MARKETS LLC |
| 2025-11-07 | Jason PitofskyOfficer | 431 | $281K | 0.000% | 2025-11-07 | UBS Financial Services Inc |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of REGN in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 7.4% of the class (7,660,810 shares), filed 2026-04-30 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-04-30 | 13G | Vanguard Capital Managementinvestment adviser | 7.7M | 7.4% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 7 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding REGN at their latest 13F. JSON7 of the 30 tracked managers held REGN at their latest 13F, $1.40B in total at quarter-end prices. AQR Capital Management is the largest at $702.2M (0.2% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 1.1M | $702.2M | 0.24% | -105K |
| Two Sigma Investments | 2026-06-30 | 656K | $409.1M | 0.30% | -156K |
| Millennium Management | 2026-06-30 | 165K | $103.0M | 0.04% | +102K |
| Renaissance Technologies | 2026-06-30 | 148K | $92.4M | 0.13% | +81K |
| Citadel Advisors | 2026-06-30 | 58K | $35.9M | 0.00% | +10K |
| Bridgewater Associates | 2026-06-30 | 51K | $32.0M | 0.13% | +29K |
| D. E. Shaw & Co. | 2026-06-30 | 38K | $24.0M | 0.01% | +16K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q3 FY 2026 (quarter ended 2026-09-30) Regeneron Pharmaceuticals reported revenue of $5.12B, up 36.3% from the same quarter a year earlier, and net income of $1.95B (18.45 diluted EPS). In FY 2025 it generated $4.98B of operating cash flow and spent $3.44B on buybacks and $370.3M on dividends. As of 2026-09-30, cash was $3.66B against $1.99B of debt.
- Cash
- $3.66B
- Debt
- $1.99B
- Equity
- $33.50B
- Total assets
- $44.41B
- Shares outstanding
- 93,955,110
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q3 FY 2026 | 2026-09-30 | $5.12B | $1.95B | 38.1% | 18.45 |
| Q2 FY 2026 | 2026-06-30 | $4.29B | $1.30B | 30.2% | 12.23 |
| Q1 FY 2026 | 2026-03-31 | $3.61B | $727.2M | 20.2% | 6.75 |
| Q4 FY 2025derived | 2025-12-31 | $3.88B | $844.6M | 21.7% | n/a |
| Q3 FY 2025 | 2025-09-30 | $3.75B | $1.46B | 38.9% | 13.62 |
| Q2 FY 2025 | 2025-06-30 | $3.68B | $1.39B | 37.9% | 12.81 |
| Q1 FY 2025 | 2025-03-31 | $3.03B | $808.7M | 26.7% | 7.27 |
| Q4 FY 2024derived | 2024-12-31 | $3.79B | $917.7M | 24.2% | n/a |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $14.34B | $4.50B | $4.98B | $898.4M | $3.44B | $370.3M |
| FY 2024 | 2024-12-31 | $14.20B | $4.41B | $4.42B | $755.9M | $2.60B | $0 |
| FY 2023 | 2023-12-31 | $13.12B | $3.95B | $4.59B | $718.6M | $2.23B | $0 |
| FY 2022 | 2022-12-31 | $12.17B | $4.34B | $5.01B | $590.1M | $2.08B | n/a |
| FY 2021 | 2021-12-31 | $16.07B | $8.08B | $7.08B | $551.9M | $1.65B | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-09-30; shares outstanding as of 2012-07-13 from the cover page.
What this page is
Regeneron Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Regeneron Pharmaceuticals (REGN), SEC CIK 872589, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-17.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-11-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-04-30.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-09-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-10-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-14.JSON and CSV
- Company record
- EDGAR filing index for CIK 872589Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of REGN is sold short?
2,134,934 shares were held short at the 2026-10-15 settlement, 3.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is REGN's daily short volume?
On 2026-11-02, 435,521 of the 786,929 REGN shares reported to FINRA were sold short, 55.3% of the day's reported volume. Short volume is a flow for one day, not a position.
Does REGN have fails to deliver?
The SEC's latest file shows 8 REGN shares failed to deliver at settlement 2026-09-17. Fails are reported per settlement date and published twice a month with a lag.
Are REGN insiders buying or selling?
Insiders at REGN reported 32 open-market sells worth $6.5M in the last 90 days and no open-market buys. Latest filing: MURPHY ANDREW J (Co-Chief Scientific Officer) on 2026-10-14.
Have REGN insiders filed to sell?
17 Form 144 notices on file for REGN worth $39.4M at the prices reported; 11 in the last 90 days worth $34.1M. Latest: Joseph LaRosa filed on 2026-11-02 to sell 4,466 shares ($4.3M) from 2026-11-02.
Who owns 5% or more of REGN?
1 holder reports 5% or more of REGN in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 7.4% of the class (7,660,810 shares), filed 2026-04-30 for an event on 2026-03-31.
What did REGN report last quarter?
In Q3 FY 2026 (quarter ended 2026-09-30) Regeneron Pharmaceuticals reported revenue of $5.12B, up 36.3% from the same quarter a year earlier, and net income of $1.95B (18.45 diluted EPS). In FY 2025 it generated $4.98B of operating cash flow and spent $3.44B on buybacks and $370.3M on dividends. As of 2026-09-30, cash was $3.66B against $1.99B of debt.
Which tracked 13F managers own REGN?
7 of the 30 tracked 13F managers held REGN shares at their latest filing, $1.40B in all. The largest: Cliff Asness's AQR Capital Management (1.1M shares, $702.2M), Two Sigma Investments (656K shares, $409.1M), Izzy Englander's Millennium Management (165K shares, $103.0M), Renaissance Technologies (148K shares, $92.4M), Ken Griffin's Citadel Advisors (58K shares, $35.9M), Ray Dalio's Bridgewater Associates (51K shares, $32.0M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.